Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 612 across all filing types
Latest filing 2021-09-30 Regulatory Filings
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Alligator Bioscience meddelar att första patienten doserats i den kliniska fas-II-studien OPTIMIZE-1 som utvärderar mitazalimab i kombination med mFOLFIRINOX för behandling av bukspottkörtelcancer
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience, dated September 30, 2021, announcing that the first patient has been dosed in the Phase II clinical trial OPTIMIZE-1 for their drug mitazalimab. It details the trial's purpose, timeline (interim results expected Q1 2022 and Q4 2022), and provides quotes from the CEO and a principal investigator. This type of announcement, focusing on the initiation of a clinical trial phase and providing key operational updates, is characteristic of an announcement related to ongoing drug development or financing activities, but it is not a formal regulatory filing like a 10-K, a full earnings release (ER), or a formal capital update (CAP). Since it announces progress in drug development and the initiation of a study, it most closely aligns with general corporate news that might be released via a regulatory channel. Given the options, and since it is a specific announcement of a clinical milestone rather than a general financial report or a specific transaction, it fits best under the general 'Regulatory Filings' (RNS) category as a significant corporate event announcement, or potentially a specialized 'Capital/Financing Update' (CAP) if the trial initiation was tied to specific funding milestones, but RNS is the safer general category for non-standard press releases. However, looking closely at the definitions, none perfectly capture a 'Clinical Trial Milestone Announcement'. Since it is a formal announcement released to the public (indicated by the contact/release time information), and it is not a specific financial report, it defaults to the general regulatory announcement category.
2021-09-30 Swedish
Alligator Bioscience Announces First Patient Dosed in OPTIMIZE-1 Phase II Clinical Trial Evaluating Mitazalimab in Combination with mFOLFIRINOX for the Treatment of Pancreatic Cancer
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience announcing that the first patient has been dosed in their Phase II clinical trial (OPTIMIZE-1) for a drug called Mitazalimab. It details the trial's purpose, combination therapy (mFOLFIRINOX), expected readouts (Q1 2022, Q4 2022), and includes quotes from the CEO and a principal investigator. This type of announcement, focusing on clinical trial progress, safety, and efficacy updates, is typically classified as an Investor Presentation (IP) if it were a deck, or often falls under general Investor Relations/Regulatory Filings. However, given the specific definitions, it is not a full Annual Report (10-K), an Earnings Release (ER), or a Call Transcript (CT). It is a specific update on drug development, which often accompanies or precedes a formal Investor Presentation or is released as a general regulatory update. Since it is a specific announcement about a clinical trial milestone and future readouts, it aligns best with the content typically found in an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the detailed nature of the clinical update and the context of providing information to investors about pipeline progress, IP is a strong candidate, but RNS serves as the best general regulatory announcement fallback for specific, non-standard updates. Since it is a direct announcement of a clinical event, and not a formal financial report, RNS is the most appropriate general classification for this type of corporate news release.
2021-09-30 English
Alligator Bioscience undersöker finansieringsalternativ för att stödja fas II-studier för Mitazalimab, fas II-förberedelser för ATOR-1017 samt utvecklingen av andra pipelinekandidater
Capital/Financing Update Classification · 1% confidence The document is a press release from Alligator Bioscience announcing that the company will explore financing alternatives, potentially including issuing shares, to support ongoing clinical trials (Mitazalimab Phase II, ATOR-1017 Phase II preparations) and pipeline development. The text explicitly mentions strengthening working capital and evaluating financing options, which directly relates to capital structure and fundraising activities. This aligns best with the 'Capital/Financing Update' category (CAP). The document is short and appears to be an initial announcement, not a detailed prospectus or a full regulatory filing like a 10-K or IR.
2021-09-02 Swedish
Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline
Capital/Financing Update Classification · 1% confidence The document explicitly states that Alligator Bioscience AB is 'exploring financing alternatives' and mentions that these alternatives 'may include issuance of equity.' It further notes that the Board has appointed financial advisors and that working capital needs to be strengthened to fund ongoing studies. This content directly relates to fundraising, capital structure decisions, and financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short (2592 chars), but its primary purpose is to announce the *intent* to seek financing, not just to announce the publication of a separate report.
2021-09-02 English
Alligator Bioscience ingår immunonkologiskt forskningssamarbete och licensavtal med Orion Corporation
Regulatory Filings Classification · 1% confidence The document is a press release dated August 18, 2021, announcing a research collaboration and licensing agreement between Alligator Bioscience and Orion Corporation regarding cancer treatments. The text details the terms of the agreement (upfront payment, milestones, royalties) and includes quotes from management. The concluding paragraph states: "Denna information är sådan information som Alligator Bioscience AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." This indicates a mandatory regulatory disclosure concerning a significant corporate event (a major partnership/licensing deal). This type of announcement, which is not a standard periodic report (10-K, IR), a specific financial event (DIV, CAP), or a management change (MANG), fits best under the general category for regulatory announcements that must be made public, which is Regulatory Filings (RNS). It is too detailed to be a simple Report Publication Announcement (RPA) and does not match any other specific category.
2021-08-18 Swedish
Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation
Capital/Financing Update Classification · 1% confidence The document is an announcement detailing a 'research collaboration and license agreement' between Alligator Bioscience and Orion Corporation regarding the discovery and development of bispecific antibody cancer therapeutics. It includes financial terms (upfront payment, milestone payments up to 469 million euros) and quotes from management. This type of announcement, concerning strategic partnerships, licensing deals, and potential future financing/development milestones, most closely aligns with the 'Capital/Financing Update' category, as it details a significant financial arrangement and future revenue potential derived from R&D activities. While it is an announcement, it is not announcing the publication of a standard periodic report (like 10-K or IR), nor is it a general regulatory filing (RNS). It is a specific corporate transaction announcement. Therefore, 'CAP' (Capital/Financing Update) is the most appropriate classification.
2021-08-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.